Researchers from Kessler Foundation and Kessler Institute for Rehabilitation (collectively "Kessler") conducted the first prospective study to assess whether transcutaneous spinal stimulation (TSS) ...

A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection ...

A revolutionary jab that could repair spinal cord injuries has been developed by scientists. Paralyzed mice regrew nerves within 3 months following weekly injections, according to a new study. The ...

The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in adults and pediatric patients 2 years and older with a confirmed mutation in ...

A retrospective, single-center study out of the Czech Republic tested the safety and efficacy of unilateral interlaminar fenestration (UILF) on the convex side in cases of SMA that also exhibit severe ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline to 6 months in both patient groups were similar by Upper Extremity Measurement Scale scores ...

Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord. Their research, published ...

PRIALT ® (ziconotide) is the only FDA-approved, non-opioid intrathecal infusion treatment option for patients suffering from severe chronic pain for whom intrathecal therapy is warranted, and who are ...

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in ...

Accidents, falls, and certain diseases can injure the spinal cord. How a spinal cord injury affects a person depends on two factors: the area of the spinal cord where the injury occurred and the ...